All In MedTech

FDA Clearance Tracker · P150025-S014

PD-L1 IHC 28-8 pharmDx

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 18, 2021 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 18, 2021

Approved

Time to decision

98 days

Received Jul 12, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P150025-S014
Device name
PD-L1 IHC 28-8 pharmDx
Applicant location
Santa Clara, CA
Received
Jul 12, 2021
Decided
Oct 18, 2021
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P150025

Device type

Device class
Class III

Every decision under product code PLS

FDA's approval statement

As written in FDA's record.

Approval to update the current approved urothelial carcinoma (UC) indication of PD-L1 IHC 28-8 pharmDx: to include enhanced disease-free survival and new clinical data from Bristol-Myers Squibb (BMS) clinical study CA209274 (CHECKMATE-274) in this existing indication.PD-L1 IHC 28-8 pharmDx is a qualitative immunohistochemical assay using Monoclonal Rabbit Anti-PD-L1, Clone 28-8 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), and urothelial carcinoma (UC) tissues using EnVision FLEX visualization system on Autostainer Link 48. PD-L1 protein expression is defined as the percentage of evaluable tumor cells exhibiting partial or complete membrane staining at any intensity.Companion Diagnostic IndicationTumor Indication PD-L1 ExpressionClinical Cutoff Intended UseNSCLC >= 1% tumor cell expression PD-L1 ICH 28-8 pharmDx is indicated as an aid in identifying NSCLC patients for treatment with OPDIVO (nivolumab) in combination with YERVOY (ipilimumab).When used in accordance with approved therapeutic labeling:PD-L1 expression (>= 1% or >= 5% or >= 10% tumor cell expression), as detected by PD-L1 IHC 28-8 pharmDx in non-squamous NSCLC (nsNSCLC) may be associated with enhanced survival from OPDIVO.PD-L1 expression (>= 1% tumor cell expression), as detected by PD-L1 IHC 28-8 pharmDx in SCCHN may be associated with enhanced survival from OPDIVO.PD-L1 expression (>= 1% tumor cell expression), as detected by PD-L1 IHC 28-8 pharmDx in UC may be associated with enhanced response rate and enhanced disease-free survival from OPDIVO®.See the OPDIVO® and YERVOY® product labels for specific clinical circumstances guiding PD-L1 testing.

Source documents

Other decisions for Agilent Technologies, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.